Stone, J.H., Merkel, P.A., Spiera, R., Seo, P., Langford, C.A., Hoffman, G.S., Kallenberg, C.G., St Clair, E.W., Turkiewicz, A., Tchao, N.K., Webber, L., Ding, L., Sejismundo, L.P., Mieras, K., Weitzenkamp, D., Ikle, D., Seyfert-Margolis, V., Mueller, M., Brunetta, P., Allen, N.B., Fervenza, F.C., Geetha, D., Keogh, K.A., Kissin, E.Y., Monach, P.A., Peikert, T., Stegeman, C., Ytterberg, S.R. and Specks, U. (2010) Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. New England Journal of Medicine, 363, 221-232.
http://dx.doi.org/10.1056/NEJMoa0909905

has been cited by the following article:

• TITLE: ANCA-Associated Vasculitides—An Update

  AUTHORS: Johanna Kegel, Torsten Kirsch

  KEYWORDS: Vasculitis, Anti-Neutrophil Cytoplasmic Antibodies, Neutrophils

  JOURNAL NAME: Health, Vol.6 No.14, July 28, 2014

  ABSTRACT: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides are characterized by destruction of small vessels, granulomatous inflammation of the respiratory tract and necrotizing glomerulonephritis. This review describes the clinical diagnosis and therapy as well as the patho-physiology of ANCA-associated vasculitides with a specific focus on the interplay of ANCAs with activated neutrophils and the deleterious pathophysiological consequences of neutrophil-endothelium interaction.